Arbutus provides 2024 outlook: $132M cash, reduced burn, multiple Phase 2a readouts expected in 1H 2024

Arbutus Biopharma Corp

Cash, equivalents and investments ~$132M at Dec 31, 2023; net burn expected $63-67M in 2024 vs ~$85M in 2023.
Cash runway extends into Q1 2026.
End-of-treatment data from imdusiran Phase 2a trials AB-729-201 and AB-729-202 expected 1H 2024.
Third Phase 2a imdusiran trial (AB-729-203, with durvalumab) to begin in 1H 2024; AB-101 Phase 1a/1b data also expected 1H 2024.
Moderna LNP claim construction hearing set Feb 8, 2024; trial expected 1H 2025. Pfizer/BioNTech lawsuit ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.